ArticleJournal of inflammation research2026
Mechanism of BMSCs Inhibiting Microglia Activation and Neuroinflammatory Response to Alleviate BCP by Regulating TLR4/ NF-κB Signaling Pathway.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone marrow mesenchymal stem cells (BMSCs) are effective in treating a variety of chronic pain conditions, including bone cancer pain (BCP); however, the underlying mechanism remains unclear. Microglia are the main cells involved in hyperalgesia and maintenance of BCP. Hence, their activation and polarization are key signs of neuroinflammation. The Toll-like receptor 4/ nuclear factor-kappa B (TLR4/ NF-κB) signaling pathway plays an essential role in microglial activation and neuroinflammation. Nonetheless, whether BMSCs can be used to treat BCP by regulating the TLR4/NF-κB signaling pathway and microglial activation requires further research. In this study, a series of experiments were conducted to explore the specific mechanisms underlying the beneficial effects of BMSCs on BCP. Methods: Initially, this study demonstrated the therapeutic effect of BMSCs on BCP through behavioral and pathological evaluations. Subsequently, the effects of BMSCs on microglia and related mechanisms were detected by Western blotting, immunofluorescence, ELISA, and RNA sequencing. Finally, based on the microglia BV2-BMSCs co-culture model, the mechanism of BMSCs regulation of microglia was further verified through in vitro experiments. Results: Intrathecal injection of BMSCs was found to alleviate BCP by inhibiting the activation of microglia in the spinal dorsal horn and the release of cytokines, which involves the regulation of the TLR4/NF-kB signaling pathway. In addition, BMSCs inhibited the nuclear transport of NF-κB in vitro. Discussion: These results revealed that the TLR4/NF-κB signaling pathway in microglia is one of the targets of BMSCs in BCP treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.